Project Updates and Milestones news (page 4)

• 

  9 June 2026

  QatarEnergy discovers oil at Merlin-1X offshore Namibia

  Merlin-1X in PEL 0039 shows light oil, good reservoir quality and limited associated gas; it is the tenth well drilled under the licence.
• 

  9 June 2026

  DuPont MemCor MBR chosen for Riverstone WRRF upgrade

  MemCor MBR will provide 24.8 MLD average (86 MLD peak) capacity using 2,592 MemPulse B50 modules for the Riverstone WRRF upgrade in Sydney’s North West.
• 

  9 June 2026

  Plenitude commissions 330 MW Renopool PV plant in Spain

  Southern 200 MW block started operations, completing the 330 MW Renopool complex in Extremadura; the site uses bifacial modules and targets about 670 GWh/year.
• 

  9 June 2026

  Takeda: FDA accepts sBLA for IV ENTYVIO in pediatric UC and Crohn’s

  FDA accepted an sBLA to extend IV vedolizumab (ENTYVIO) to children aged 2+ with moderately to severely active UC and Crohn’s; PDUFA Q1 2027.
• 

  9 June 2026

  Honeywell launches Experion Cognition for autonomous control rooms at Borouge Ruwais

  AI-enabled control system makes predictive recommendations and automated decisions to reduce anomalies, increase production and compensate for operator skill gaps; commercial from Q3 2026.
• 

  9 June 2026

  European Commission launches €1.5bn Battery Booster Facility

  Mobilises up to €1.5bn from ETS revenues as interest‑free loans to scale EV battery cell production in the EEA; call opens Q3 2026.

• 

  9 June 2026

  PureCycle & Innovia Films produce white, cavitated BOPP using PureFive Choice™ recycled PP

  White, cavitated BOPP film made with >40% post‑consumer recycled polypropylene showed virgin‑like processing and comparable mechanical, barrier and sealing performance.
• 

  9 June 2026

  Covestro Bayblend T85X R35 CQ (35% PCR PC/ABS) adopted for Lexus ES interiors

  35% post-consumer recycled PC/ABS approved for visible Lexus ES interior parts; material claims 25% lower CO2e GWP vs fossil-based alternatives and was co-developed with Toyota and Kojima.
• 

  9 June 2026

  thyssenkrupp Uhde wins pre‑FEEDs for Fuella’s 2×400 ktpa green ammonia projects in Brazil

  Pre‑FEEDs will optimise concept and integration for two 400 ktpa renewable‑powered ammonia plants at Pecém and Açu, covering electrolysis, balance of plant and ammonia offloading.
• 

  9 June 2026

  Technip Energies, Airbus, Safran and Tereos form Rebound JV to build 160,000 t/y Alcohol‑to‑Jet SAF at Dunkirk

  JV to develop a 160,000 t/y Alcohol‑to‑Jet SAF plant at Port of Dunkirk; partners will fund development, run pre‑FEED/FEED and seek FID after permitting, feedstock and offtake agreements.
• 

  9 June 2026

  PTT Global Chemical positions Map Ta Phut as regional hub for high‑value, low‑carbon businesses with Toray and Mitsubishi

  Turning agricultural residues into bio‑based chemicals; trialled at 50,000‑L fermentation scale; pilot‑scale bio muconic and adipic acid targeted by 2028; pathway to 100% bio‑based nylon 6,6 and expanded market access.
• 

  8 June 2026

  Honeywell reaffirms 2026 guidance and issues Honeywell Technologies outlook

  Full-year sales $38.8–39.8B; adjusted EPS $10.35–10.65 and free cash flow $5.3–5.6B. Post-spin Honeywell Technologies sales $19.9–20.2B; adjusted EPS $3.95–4.15.
• 

  8 June 2026

  Uniper and Ksi Lisims LNG sign LOI for 2 mtpa Canadian LNG supply

  LOI outlines a 2 mtpa long-term LNG purchase, with first volumes possible in 2032 from a proposed 12 mtpa BC floating export facility designed for low emissions.
• 

  8 June 2026

  Lilly's Foundayo (orforglipron) outperforms oral semaglutide, dapagliflozin and placebo in ACHIEVE trials

  Oral GLP‑1 orforglipron reduced A1C and body weight more than oral semaglutide, dapagliflozin or placebo across three Phase‑3 trials; FDA filing planned by end of Q2 2026.
• 

  8 June 2026

  Gilead and Merck: Phase 3 ISLEND trials show positive topline results for once‑weekly islatravir/lenacapavir

  Once‑weekly oral islatravir 2 mg/lenacapavir 300 mg met Week 48 primary endpoint, non‑inferior to Biktarvy and daily standard‑of‑care; safety profile comparable across arms.
• 

  8 June 2026

  Merck and Gilead discontinue Phase 3 KEYNOTE‑D46/EVOKE‑03 (Trodelvy + KEYTRUDA) in PD‑L1 ≥50% mNSCLC

  eDMC recommended stopping the Phase 3 trial after final PFS and interim OS reviews: PFS trend non‑significant, OS unlikely to be significant; safety profile consistent; ~620 patients enrolled.
• 

  8 June 2026

  Meccanoplastica showcases INEOS recycled HDPE at PLAST 2026

  Live blow-moulding demo will produce 200ml cosmetic bottles with advanced recycled HDPE; 4L samples use Recycl-IN HDPE with 50% post‑consumer recyclate to support regulatory targets.
• 

  8 June 2026

  Iberdrola (Neoenergia) to invest €4.5bn in Bahia power networks to 2030

  Nearly €4.5bn (25bn reais) planned for Bahia to 2030 to expand, modernise and digitalise networks and connect new industries with 54 substations and extensive HV/MV lines.
• 

  8 June 2026

  Technip Energies wins EPCIC contract for Coral Norte FLNG with JGC and Samsung Heavy

  Coral Norte FLNG will produce ~3.6 Mtpa, doubling the Coral hub to 7 Mtpa and placing Mozambique among Africa’s top three LNG producers.
• 

  8 June 2026

  ORLEN launches small‑scale LNG and bioLNG market demand survey

  Survey collects customer forecasts on volumes, delivery points and fuel-use models to shape future small‑scale LNG/bioLNG infrastructure and commercial offers; open until end of June.
• 

  8 June 2026

  Aurubis Italia first site in Italy awarded The Copper Mark

  Avellino rod plant becomes first in Italy to gain The Copper Mark, completing certification of all four rod plants and expanding verified coverage across the group's production network.
• 

  8 June 2026

  Roche and Nurix partner to co-develop and co-commercialise BTK degrader bexobrutideg

  Collaboration targets B‑cell malignancies, immunology and neurology with an oral, brain‑penetrant BTK degrader planned for Phase 3 in summer 2026.
• 

  7 June 2026

  Boehringer Ingelheim: Survodutide Phase III shows up to 34% visceral and 63% liver fat reduction with limited lean mass loss

  Phase III data show targeted visceral and liver fat reductions with minimal lean mass loss and sustained weight loss in obesity and MASLD populations.
• 

  7 June 2026

  Novo Nordisk CagriSema Phase 3 trials show large HbA1c and weight reductions

  Once‑weekly cagrilintide+semaglutide reduced HbA1c by up to 2.33 percentage points and bodyweight by up to 14.2% across REIMAGINE 1–3 versus comparators.
• 

  7 June 2026

  Lilly Foundayo shows weight loss across pre-, peri- and post‑menopause

  Orforglipron produced meaningful body‑weight and waist reductions across menopausal stages in ATTAIN‑1 and ATTAIN‑2, including women with type 2 diabetes.
• 

  7 June 2026

  Amgen: Repatha (evolocumab) cuts first major CV events 29% in high‑risk diabetes subgroup

  VESALIUS‑CV subgroup shows evolocumab lowers first major cardiovascular events and LDL‑C; real‑world GLP‑1 persistence is low, curbing potential benefits.
• 

  6 June 2026

  Lilly's retatrutide shows major weight loss and benefits for diabetes, knee osteoarthritis and OSA

  Triple agonist produced up to 28.3% weight loss at 80 weeks, A1C fell up to 2.0% at 40 weeks, with large reductions in knee pain and sleep apnea severity.
• 

  6 June 2026

  Novo Nordisk: semaglutide (Wegovy) post‑hoc data across cardiometabolic conditions

  Post‑hoc analyses link semaglutide to lower OSA incidence, fewer asthma events, improved systolic BP, and liver and cardiometabolic improvements across SELECT, STEP, ESSENCE and OASIS trials.
• 

  5 June 2026

  Röhm opens Bay City MMA plant as LiMA technology reaches full industrial scale

  Proprietary LiMA process reaches full industrial scale; Bay City becomes North America’s first C2‑based MMA site with 250,000 tpa capacity and enhanced sustainability measures.
• 

  5 June 2026

  Novo Nordisk zenagamtide (amycretin) delivers large HbA1c and weight reductions in phase 2 T2D trial

  Unimolecular GLP‑1/amylin agonist produced substantial HbA1c and weight reductions in a 36‑week phase 2 trial in adults with type 2 diabetes on metformin ± SGLT2i.